Lowell E. Sears has been Chairman and Chief Executive Officer of Sears Capital Management, Inc., a life sciences venture capital and portfolio management company, since 1994. Prior to founding Sears Capital Management, Mr. Sears was Chief Financial Officer of Amgen, Inc. from 1988 to 1994 as well its Senior Vice President responsible for the Asia-Pacific region.

Mr. Sears served as Amgen's Treasurer and Director of Planning from 1986 to 1988. From 1976 to 1986, Mr. Sears held senior financial and planning positions with Atlantic Richfield Company, an integrated oil company, including several years as Chief Financial Officer of its Ventures Division. Mr. Sears received his B.A. degree in economics from Claremont McKenna College and his M.B.A. from Stanford University.

Mr. Brand brings more than 30 years of global pharmaceutical experience in product development, acquisitions, marketing and operational management with GlaxoSmithKline, its predecessor companies, and most recently as President and CEO of Cardiokine.

Mr. Brand joined GSK International from the Canadian operation in 1983 in the post of Vice President, Cardiovascular/Gastrointestinal Marketing. Over the next 7 years, he held VP positions in marketing, business development, and regional operations in Asia, Europe and Latin America.

In 1990, Mr. Brand joined the GSK US organization as Business Unit Head for Gastrointestinal and Central Nervous System Products, where he led the launch activities for Paxil and Kytril. In 1994, as Vice President of New Product Planning, he was responsible for the pre-launch commercial development plans for Coreg, Hycamptin, Requip and numerous in-licensing, co-promotion, co-development partnerships. From 1997 through 2003, Mr Brand headed up the anti-infective, metabolic and cardiovascular business units that launched Requip, Avandia and Avandia extensions, and development of Augmentin ES/XR.

From 2004 to September 2007, Mr. Brand served as President and CEO of Cardiokine, a specialty pharmaceutical company developing lixivaptan. Over this period, Mr. Brand built a first class management and development team, successfully closed a $50 million Series B financing and completed a global lixivaptan co-development, co-marketing agreement with Biogen Idec.

Mr. Brand holds a Bachelor of Commerce degree from Concordia University in Montreal, Canada.

Martin Freed, M.D., spent nearly 14 years at GlaxoSmithKline and its predecessor, SmithKline Beecham Pharmaceuticals. He was Vice President, Clinical in the Metabolism Therapeutic Area, where he led clinical development for diabetes and obesity drugs. For over 12 years, Dr. Freed played a substantial role in the development of the Avandia-related franchise. He personally managed the clinical pharmacology development and subsequently led a team responsible for clinical development, life cycle management, and medical affairs of the GSK diabetes franchise, including Avandia, Avandamet and Avandaryl. From 2005 to 2007, Dr. Freed served as Chief Medical Officer at Vitae Pharmaceuticals, Inc.. Since June 2007, Dr. Freed has served as Chief Medical Officer at Adnexus Therapeutics, which discovers and develops a novel, proprietary class of targeted biologics called Adnectins™.

Dr. Freed has been involved in the clinical development of drugs across a broad range of therapeutic areas including metabolic diseases, cardiovascular disease and diseases of inflammation with experiences ranging from Phase I through Phase IV. He has authored over 100 publications or presentations. A Fellow of the American College of Physicians, Dr. Freed received his Doctor of Medicine from Pennsylvania State University’s College of Medicine and graduated magna cum laude with a Bachelor of Arts with Distinction in Biology from the University of Delaware. Dr. Freed is Board Certified in Internal Medicine, Nephrology and Clinical Pharmacology. He performed his internal medicine residency and nephrology fellowship at Temple University Hospital and Yale New Haven Hospital, respectively.

Jim Healy, M.D., Ph.D., General Partner, joined Sofinnova in the spring of 2000. In the words of one entrepreneur, Jim has an "unparalleled work ethic." Prior to joining Sofinnova, he had experience with both pharmaceutical products and research platforms. In the pharmaceutical industry he held a manufacturing position at Bayer Pharmaceuticals (Miles) and helped guide the discovery group at ISTA Pharmaceuticals prior to its initial public offering. He also has experience with research tools and platforms through his involvement at the Human Genome Center at Lawrence Berkeley Labs.

Jim has authored or co-authored numerous research articles and reviews, including three papers published in Nature. He began his private equity career at Sanderling. Jim earned B.A.s in Molecular Biology and Scandinavian Studies from the University of California at Berkeley, where he graduated with Distinction in General Scholarship, Honors, and received the Departmental Citation. Jim received his M.D. from Stanford School of Medicine through the Medical Scientist Training Program, and earned his Ph.D. in Immunology from Stanford University, where he was a Beckman Scholar and received a bursary award from the Novartis Foundation.

Mr. Lanfear is Founder, President and Chief Executive of InteKrin Therapeutics, Inc. Denny is a thirteen year veteran of Amgen, Inc. where he was a Corporate Officer and Vice-President with broad operational, product development and marketing responsibility. His tenure began in 1986 as founder of the Process Development Department.

Under his ten-year leadership this group became the preeminent PD organization in BioPharma and a key strategic advantage for the company, as it remains today. As Vice President Process Development and Operations Systems, he directed the business process integration of over twenty-five hundred Operations and Quality staff world-wide.

While at Amgen he also had senior leadership roles in several product development programs including those for growth factors, somatotrophins and neurotrophins, directing efforts from preclinical to Phase III. He reviewed and wrote sections of more that 20 INDs and several BLAs. He managed several corporate partner relationships including that with SKB from 1986 to 1990. He also managed and had direct budgetary responsibility for the $135M development partnership with Regeneron Pharmaceuticals from 1991 to 1999. In 1997 he was named Vice President, Market Development, where he defined long term competitive and reimbursement strategies for EpogenTM, a multibillion dollar drug.

Prior to joining Amgen, Denny held positions of increasing responsibility at Baxter International. Denny was also the founder and former CEO of Saronyx, Inc., a drug development software services company. He is also an active life science investor through his firm Lanfear Capital Advisers, which invests in pharmaceutical and medical device companies. He is an investor and former Director of Anthera Pharmaceuticals and an investor and Board observer at EndoVx, a medical device company focused on obesity.

Other investments include Coapt Systems and BAS Medical. Lanfear Capital is also Limited Partner in select venture funds. Denny earned degrees in Biochemistry and Chemical Engineering from Michigan State University and earned his MBA from the Anderson School at UCLA.

David has been involved as a research scientist, manager and leader of drug discovery programs, and advisor and investor in life sciences companies since 1985. Trained as a molecular biologist, he was at Genentech (NYSE:DNA) for 16 years, and was Director of Cardiovascular Research there from 1993 to 1999. At Genentech, David led drug discovery activities in biologics and small molecule therapeutics. He was responsible for drug discovery efforts that resulted in eight drug candidates taken into clinical development, including the successful cancer therapy Avastin™. David was a member of the therapeutic area team responsible for cardiovascular strategic planning and product portfolio management, and worked extensively with Business Development on in-licensing of early and late-stage therapeutics, and technology access. David holds BS and PhD degrees in biochemistry from the University of Toronto, Canada. He has authored over 60 peer-reviewed scientific publications and is an inventor on 7 issued or pending US patents. He is a member of the Advisory Board of the Institute of Molecular Medicine at the University of California, San Diego. He joined Skyline in 2002 as a Kauffman Fellow, and became a partner in 2003. He is an ardent SCUBA diver, underwater photographer, and (perhaps because he believes the financial warning that past results do not necessarily predict future performance) roots for either the Red Sox or Yankees depending on who's winning.

Harold E. "Barry" Selick, Ph.D. has been Chief Executive Officer of Threshold Pharmaceuticals since May 2003. Since June 2002, Dr. Selick has been a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc.. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for treating kidney transplant rejection.

Dr. Selick also serves on the Board of Directors of DiObex, Inc. and Catalyst Biosciences. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.

Samuel P. Wertheimer, Ph.D., Dr. Wertheimer joined OrbiMed in 2000 and is a Principal in the private equity funds management group. Dr. Wertheimer’s prior experience includes work in biotechnology finance, technology transfer, intellectual property and research in immunology and molecular biology.

Dr. Wertheimer was a Fellow at the Memorial Sloan-Kettering Cancer Center. Dr. Wertheimer received a Ph.D. in Molecular Biology from New York University, an M.P.H. from Yale University and a B.A. from The Johns Hopkins University. He has served as a Director of Salmedix and Corus Pharma and currently serves on the boards of several private biotechnology companies including Biodel and ChemoCentryx.